Paracetamol versus placebo in treatment of non-severe malaria in children in Guinea-Bissau: a randomized controlled trial

Poul-Erik Kofoed, Johan Ursing, Amabelia Rodrigues, Lars Rombo, Poul-Erik Kofoed, Johan Ursing, Amabelia Rodrigues, Lars Rombo

Abstract

Background: The current guidelines for treatment of malaria include paracetamol to children with fever. No convincing evidence for the beneficial effects of this practice exists. Studies show that time to parasite clearance is significantly longer in children treated with paracetamol, which questions the policy. Whether this is of clinical importance has not been investigated.

Methods: Children with Plasmodium falciparum monoinfection and ≥20 parasites per 200 leucocytes at the Bandim Health Centre, Guinea-Bissau were randomized to receive paracetamol or placebo together with chloroquine for three days in a double blind randomized study. Temperature and symptoms were recorded twice daily during treatment and on day 3. The participants were interviewed and a malaria film taken once weekly until day 35. The data is in the form of grouped failure-times, the outcome of interest being time until parasitaemia during follow-up. Mantel-Haenszel weighted odds ratios are given. Other differences between and within the two groups have been tested using the Chi-square test and Mann-Whitney U test.

Results: In the evening of the day of inclusion, the temperature was slightly, but statistically insignificant, higher in the placebo group and significantly more children complained of headache. At no other time was a significant difference in temperature or symptoms detected. However, 6 children from the placebo-group as compared to two children from the paracetamol-group were admitted to hospital with high fever and convulsions by day 3. No differences in the cumulative percentages of children with adequate clinical and parasitological response were found in the intention-to-treat analysis or in the per-protocol analysis.

Conclusion: Fewer children had early treatment failure and the mean temperature was slightly lower in the afternoon on day 0 in the paracetamol group. However, the cumulative adequate clinical and parasitological cure rates were not significantly different during the period of study. It is doubtful whether adding paracetamol to the treatment of uncomplicated malaria in children is beneficial.

Trial registration: NCT00137566.

Figures

Figure 1
Figure 1
The reasons for lost to follow-up were mainly due to the children travelling outside the study-area (20 and 16 in paracetamol and placebo groups, respectively). One child in the paracetamol group withdrew consent on day 14 and for one child in each of the study groups no information could be obtained. Due to the staff being involved in the national vaccination campaign 2 children were lost to follow-up on day 28 and 3 on day 35. LPF/LCF: including children treated outside the study. *: Including one child from each of the groups admitted to hospital. **: Including one child in the paracetamol group admitted to hospital.

References

    1. Roberts NJ Jr. Impact of temperature elevation on immunologic defenses. Rev Infect Dis. 1991;10:462–472. doi: 10.1093/clinids/13.3.462.
    1. El-Radhi AS. Is Fever Beneficial? Berlin: Springer-Verlag; 2009.
    1. Meremikwu M, Oyo-Ita A. Paracetamol versus placebo or physical methods for treating fever in children (Review) Cochrane Database Syst Rev. 2009. p. CD003676.
    1. Russell FM, Shann F, Curtis N, Mulholland K. Evidence on the use of paracetamol in febrile children. Bull World Health Organ. 2003;10:367–372.
    1. Ranganathan SS, Sathiadas MG, Sumanasena S, Fernandopulle M, Lamabadusuriya SP, Fernandopulle BM. Fulminant hepatic failure and paracetamol overuse with therapeutic intent in febrile children. Indian J Pediatr. 2006;10:871–875. doi: 10.1007/BF02859276.
    1. Heubi JE, Barbacci MB, Zimmerman HJ. Therapeutic misadventures with acetaminophen: hepatoxicity after multiple doses in children. J Pediatr. 1998;10:22–27. doi: 10.1016/S0022-3476(98)70479-2.
    1. Penna A, Buchanan N. Paracetamol poisoning in children and hepatotoxicity. Br J Clin Pharmacol. 1991;10:143–149.
    1. Kwiatkowski D. Tumour necrosis factor, fever and fatality in falciparum malaria. Immunol Lett. 1990;10:213–216. doi: 10.1016/0165-2478(90)90117-9.
    1. Karunaweera ND, Grau GE, Gamage P, Carter R, Mendis KN. Dynamics of fever and serum levels of tumor necrosis factor are closely associated during clinical paroxysms in Plasmodium vivax malaria. Proc Natl Acad Sci USA. 1992;10:3200–3203. doi: 10.1073/pnas.89.8.3200.
    1. Playfair JH, Taverne J. Antiparasitic effects of tumour necrosis factor in vivo and in vitro. Ciba Found Symp. 1987;10:192–205.
    1. Kwiatkowski D. Febrile temperatures can synchronize the growth of Plasmodium falciparum in vitro. J Exp Med. 1989;10:357–361. doi: 10.1084/jem.169.1.357.
    1. Krishna S, Supanaranond W, Pukrittayakamee S, ter KF, Supputamangkol Y, Attatamsoonthorn K. et al.Fever in uncomplicated Plasmodium falciparum infection: effects of quinine and paracetamol. Trans R Soc Trop Med Hyg. 1995;10:197–199. doi: 10.1016/0035-9203(95)90494-8.
    1. Brandts CH, Ndjave M, Graninger W, Kremsner PG. Effect of paracetamol on parasite clearance time in Plasmodium falciparum malaria. Lancet. 1997;10:704–709. doi: 10.1016/S0140-6736(97)02255-1.
    1. W.H.O. Guidelines for the treatment of malaria. 2010.
    1. Beasley R, Clayton T, Crane J, von ME, Lai CK, Montefort S, Stewart A. ISAAC Phase Three Study Group. Association between paracetamol use in infancy and childhood, and risk of asthma, rhinoconjunctivitis, and eczema in children aged 6-7 years: analysis from Phase Three of the ISAAC programme. Lancet. 2008;10:1039–1048. doi: 10.1016/S0140-6736(08)61445-2.
    1. Kofoed PE, Lopez F, Johansson P, Sandstrom A, Hedegaard K, Aaby P, Rombo L. Treatment of children with Plasmodium falciparum malaria with chloroquine in Guinea-Bissau. Am J Trop Med Hyg. 2002;10:28–31.
    1. Kofoed PE, Ursing J, Poulsen A, Rodrigues A, Bergquist Y, Aaby P, Rombo L. Different doses of amodiaquine and chloroquine for treatment of uncomplicated malaria in children in Guinea-Bissau: implications for future treatment recommendations. Trans R Soc Trop Med Hyg. 2007;10:231–238. doi: 10.1016/j.trstmh.2006.05.008.
    1. Kofoed PE, Poulsen A, Co F, Hedegaard K, Aaby P, Rombo L. No benefits from combining chloroquine with artesunate for three days for treatment of Plasmodium falciparum in Guinea-Bissau. Trans R Soc Trop Med Hyg. 2003;10:429–433. doi: 10.1016/S0035-9203(03)90078-2.
    1. Veiga MI, Ferreira PE, Bjorkman A, Gil JP. Multiplex PCR-RFLP methods for pfcrt, pfmdr1 and pfdhfr mutations in Plasmodium falciparum. Mol Cell Probes. 2006;10:100–104. doi: 10.1016/j.mcp.2005.10.003.
    1. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ. 1999;10:670–674.
    1. Adjuik M, Agnamey P, Babiker A, Borrmann S, Brasseur P, Cisse M, Cobelens F, Diallo S, Faucher JF, Garner P, Gikunda S, Kremsner PG, Krishna S, Lell B, Loolpapit M, Matsiegui PB, Missinou MA, Mwanza J, Ntoumi F, Olliaro P, Osimbo P, Rezbach P, Some E, Taylor WR. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet. 2002;10:1365–1372. doi: 10.1016/S0140-6736(02)08348-4.
    1. ClinicalTrails. . 2011. Ref Type: Online Source.
    1. Kluger MJ, Ringler DH, Anver MR. Fever and survival. Science. 1975;10:166–168. doi: 10.1126/science.1114347.
    1. Bernheim HA, Kluger MJ. Fever: effect of drug-induced antipyresis on survival. Science. 1976;10:237–239. doi: 10.1126/science.935867.
    1. Carmichael LE, Barnes FD, Percy DH. Temperature as a factor in resistance of young puppies to canine herpesvirus. J Infect Dis. 1969;10:669–678. doi: 10.1093/infdis/120.6.669.
    1. Shann F. Antipyretics in severe sepsis. Lancet. 1995;10:338. doi: 10.1016/S0140-6736(95)90337-2.
    1. Meremikwu M, Logan K, Garner P. Antipyretic measures for treating fever in malaria. Cochrane Database Syst Rev. 2009. p. CD002151.
    1. ter Kuile FO, Nosten F, Luxemburger C, Kyle D, Teja-Isavatharm P, Phaipun L, Price R, Chongsuphajaisiddhi T, White NJ. Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. Bull World Health Organ. 1995;10:631–642.
    1. Luxemburger C, van VM, Slight T, Price RN, Chongsuphajaisiddhi T, Chanthavanich P, White NJ, Nosten F. Early vomiting of mefloquine in children with malaria is not modified by the timing of antipyretic treatment. Trans R Soc Trop Med Hyg. 1998;10:562–563. doi: 10.1016/S0035-9203(98)90916-6.
    1. Strengell T, Uhari M, Tarkka R, Uusimaa J, Alen R, Lautala P, Rantala H. Antipyretic agents for preventing recurrences of febrile seizures: randomized controlled trial. Arch Pediatr Adolesc Med. 2009;10:799–804. doi: 10.1001/archpediatrics.2009.137.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi